CAS 2005/A/946 IAAF v/ FIDAL & Marco Giungi

On 25 May 2005 the National Judging Commission of the Italian Athletics Federation (FIDAL) decided to close the case against the Athlete Marco Guingi after his A and B samples tested positive for the prohibited substances 19-norandrostenedione and 19-norandrosterone (Nandrolone). Established were exceptional circumstances in this case due to the Athlete non intentially had used contamined supplements.

Hereafter in August 2005 the International Association of Athletics Federations (IAAF) appealed the FIDAL decision of 25 May 2005 with the Court of Arbitration for Sport (CAS). The IAAF requested the Panel to impose a 2 year period of ineligibility on the Athlete for committing an anti-doping rule violation.

The Athlete requested to dismiss the IAAF appeal because the IAAF had to apply its appeal with the FIDAL Appeals Commission and not with CAS and argued that no sanction had te be imposed on him on the basis of exceptional circumstances.

The Panel finds that under IAAF and FIDAL Rules, IAAF had no right to appeal the FIDAL decision of 25 May 2005 with CAS. Because the IAAF had the right to appeal the FIDAL Commission decision with the Federal Appeals Commission, but did not do so, this case ended when the time limit to make such an appeal expired.

The IAAF therefore did not have the right to make this appeal to CAS. The Panel concludes that, due to lack of jurisdiction of the Court of Arbitration for Sport, the appeal filed by the lAAF shall be dismissed.

Therefore the Court of Arbitration for Sport decides on 2 March 2006 to dismiss the IAAF appeal of 15 August 2005 against the FIDAL decision of 25 May 2005.

Facts
The French Badminton Federation (Fédération Française de Badminton, FFBad) charges respondent M18 for a violation of the Anti-Doping Rules. During a match on April 30, 2005, a sample was taken for doping test purposes. The analysis of the sample showed the presence of salbutamol which is a prohibited substance according the World Anti-Doping Agency (WADA) prohibited list.

History
The respondent used medication containing the prohibited substance to treat asthma and respiratory problems. This was mentioned on the doping control form. He needs the medication to treat an immediate asthma attack, and has pulmonary function tests reports to prove his medical state.

Decision
1. The respondent is acquitted.
2. The decision will be not be published, it will be sent to the parties involved.

Facts
The French Athletics Federation (Fédération Française d'athlétisme, FFA) charges respondent M17 for a violation of the Anti-Doping Rules. During an athletic event on November 27, 2005, respondent was asked to provide a doping sample.

History
Respondent was unable to produce enough urine for the doping test, he didn't want to wait and went home. The sample was tested anyway and the results where negative.

Decision
1. The respondent is acquitted.
2. The decision starts on the date of notification.
3. The decision will be published and sent to the parties involved.

Facts
The French Olympic Committee (Comité National Olympique et Sportif Français, CNOSF)) charges respondent M16 for a violation of the Anti-Doping Rules. During an event on October 30, 2005, a sample was taken for doping test purposes. The analysis of the sample showed the presence of a metabolite of cannabis. Cannabis is a prohibited substances according to the World Anti-Doping Agency (WADA) prohibited list.

History
The respondent admits the use of cannabis a few days before the doping control, he used it in a recreational setting among friends.

Decision
1. The sanction is a period of ineligibility of three months, from which two conditionally, in which respondent can't take part in competition or manifestations organized by the CNOSF.
2. The present decision will start on the date of notification.
3. The decision will be published and sent to the parties involved.

Facts
The French Rugby League (Fédération Française de Rugby à XIII, FFR XIII) charges respondent M15 for a violation of the Anti-Doping Rules. Respondent provided a sample for doping control purposes during a match on December 17, 2004. Analysis of the sample highlighted the presence of metabolites of nandrolone and a testosterone on epitestosterone ratio in an abnormal high level (spectro analysis shows exogenous metabolites of testosterone). Nandrolone and exogenous testosterone are prohibited substances according the World Anti-Doping Agency (WADA) prohibited list.

History
The respondent was sanctioned on May 14, 2005, for a two years period of ineligibility by the disciplinary committee of the FFR XIII. During this period he isn't allowed to take part in competition or manifestations organized or authorized by the FFR XIII.

Decision
1. The sanction by the decision of May 14, 2005, remains but will be extended to all relevant French sport federations.
2. The decision starts on the date of notification.
3. The decision will be published and sent to the parties involved.

Facts
The French Squash Federation (Fédération Française de Squash, FFSquash) charges respondent M14 for a violation of the Anti-Doping Rules. During a squash event on March 5, 2005, a sample was taken for doping control purposes. Analysis of the sample showed the presence of prednisolone, prednisone and terbutaline which are prohibited substances according the World Anti-Doping Agency (WADA) prohibited list.

History
The respondent had used medication for a medical condition he suffers from. He did mention the products on the doping control form, his medical file confirms his medical condition. However this is only a justification for the use of the medication terbutaline.

Decision
1 The sanction is a period of ineligibility of three months in which respondent can't take part in competition or manifestation organized by FFSquash.
2. The decision will start on the date of notification.
3. The decision will be published and sent to the parties involved.

Facts
The French Federation of American Football (Fédération Française de Football Américain, FFFA) charges respondent M13 for a violation of the Anti-Doping Rules. During a match on August 23, 2004, a sample was taken for doping control purposes. The analysis showed the presence of a metabolite of cannabis. Cannabis is a prohibited substances according to the World Anti-Doping Agency (WADA) prohibited list.

History
The respondent doesn't contest the allegation, he didn't send a written submission and didn't appear at the hearing.

Decision
1. The sanction is a period of ineligibility of two months, in which respondent can't take part in competition or manifestations organized or authorized by the FFFA.
2. The decision starts on the date of notification.
3. The decision will be published and sent to the parties involved.

facts
Ms Ilanit Fridman (player) was reported for a violation of the Anti-Doping Rules (ADRV). During the Open Wheelchair Tennis Championships in San Diego, California, the player provided an urine sample for a doping test. The sample tested positive for terbutaline which is a prohibited substance. After receiving notice of the positive test she took a voluntary suspension.

history
The player is paraplegic due to a car accident and confined to a wheelchair. She was diagnosed for asthma and uses an inhaler since childhood, she claims this inhaler contained the terbutaline. A doctor provided a statement she was treated with an inhalator containing salbutamol, but it is likely the doctor obtained the information from the player. The player did sent in a therapeutic use exemption (TUE) but addressed it to the wrong organization.

decision
The tribunal:
(1) confirms the commission of the doping offense specified in the notice of charge set out in the ITF’s letter to the player dated January 25, 2006: namely that a prohibited substance, terbutaline, has been found to be present in the urine specimen that the player provided on October 5, 2005, at the US Open Wheelchair Tennis Championships in San Diego, California;
(2) orders that the player’s individual result must be disqualified in respect of the singles and doubles events at the US Open Wheelchair Tennis Championships 2005, and in consequence rules that the 38 ranking points in respect of the singles event and the 75 ranking points in respect of the doubles event, and the prize money of US $78 in respect of the singles event, and of US $20 in respect of the doubles event, obtained by the player through her participation in that competition, must be forfeited;
(3) orders, further, that the player’s individual results in the competition in which she took part subsequent to the US Open Wheelchair Tennis Championships 2005, shall not be disqualified but shall remain undisturbed;
(4) finds that the player has succeeded in establishing on the balance of probabilities that her use of terbutaline leading to the positive test result was not intended to enhance sport performance;
(5) declares the player ineligible for a period of one month, running from December 24, 2005, to January 23, 2006, from participating in any capacity in any event or activity (other than authorized anti-doping education or rehabilitation programs) authorized by the ITF or any national or regional entity which is a member of or is recognized by the ITF as the entity governing the sport of tennis in that nation or region.

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults / Sam L. Teichman, Ann Neale, Betty Lawrence, Catherine Gagnon, Jean-Paul Castaigne, Lawrence A. Frohman. - (The Journal of Clinical Endocrinology & Metabolism 91 (2006) 3 (1 March); p. 799-805) 

• PMID: 16352683
• DOI: 10.1210/jc.2005-1536

Abstract

Context: Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.

Objective: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog.

Design: The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.

Setting: The study was performed at two investigational sites.

Participants: Healthy subjects, ages 21-61 yr, were studied.

Interventions: CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.

Main outcome measures: The main outcome measures were peak concentrations and area under the curve of GH and IGF-I; standard pharmacokinetic parameters were used for CJC-1295.

Results: After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d. The estimated half-life of CJC-1295 was 5.8-8.1 d. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.

Conclusions: Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent.

Drug insight : Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging Shalender Bhasin, Olga M. Calof, Thomas W. Storer, Martin L. Lee, Norman A. Mazer, Ravi Jasuja, Victor M. Montori, Wenqing Gao, James T. Dalton. - (Nature Clinical Practice Endocrinology & Metabolism 2 (2006) 3 (March); p. 146-159)

• PMID: 16932274
• PMCID: PMC2072878
• DOI: 10.1038/ncpendmet0120

Abstract

Several regulatory concerns have hindered development of androgens as anabolic therapies, despite unequivocal evidence that testosterone supplementation increases muscle mass and strength in men; it induces hypertrophy of type I and II muscle fibers, and increases myonuclear and satellite cell number. Androgens promote differentiation of mesenchymal multipotent cells into the myogenic lineage and inhibit their adipogenic differentiation, by facilitating association of androgen receptors with beta-catenin and activating T-cell factor 4. Meta-analyses indicate that testosterone supplementation increases fat-free mass and muscle strength in HIV-positive men with weight loss, glucocorticoid-treated men, and older men with low or low-normal testosterone levels. The effects of testosterone on physical function and outcomes important to patients have not, however, been studied. In older men, increased hematocrit and increased risk of prostate biopsy and detection of prostate events are the most frequent, testosterone-related adverse events. Concerns about long-term risks have restrained enthusiasm for testosterone use as anabolic therapy. Selective androgen-receptor modulators that are preferentially anabolic and that spare the prostate hold promise as anabolic therapies. We need more studies to determine whether testosterone or selective androgen-receptor modulators can induce meaningful improvements in physical function and patient-important outcomes in patients with physical dysfunction associated with chronic illness or aging.